<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">BMC Neurosci</journal-id><journal-title-group><journal-title>BMC Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1471-2202</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6090709</article-id><article-id pub-id-type="publisher-id">450</article-id><article-id pub-id-type="doi">10.1186/s12868-018-0450-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Amelioration of spinal cord injury in rats by blocking peroxynitrite/calpain activity</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7945-3237</contrib-id><name><surname>Khan</surname><given-names>Mushfiquddin</given-names></name><address><phone>(843) 792-7991</phone><email>khanm@musc.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dhammu</surname><given-names>Tajinder S.</given-names></name><address><email>Dhammu@musc.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Inderjit</given-names></name><address><email>singhi@musc.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Avtar K.</given-names></name><address><email>avtar.singh@va.gov</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2189 3475</institution-id><institution-id institution-id-type="GRID">grid.259828.c</institution-id><institution>Department of Pediatrics, 508 Children&#8217;s Research Institute, </institution><institution>Medical University of South Carolina, </institution></institution-wrap>173 Ashley Ave, Charleston, SC 29425 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8950 3536</institution-id><institution-id institution-id-type="GRID">grid.280644.c</institution-id><institution>Ralph H Johnson VA Medical Center, </institution></institution-wrap>Charleston, SC USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2189 3475</institution-id><institution-id institution-id-type="GRID">grid.259828.c</institution-id><institution>Department of Pathology and Laboratory Medicine, </institution><institution>Medical University of South Carolina, </institution></institution-wrap>Charleston, SC USA </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>8</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>8</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>19</volume><elocation-id>50</elocation-id><history><date date-type="received"><day>9</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>7</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>&#169; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Spinal cord injury (SCI) is one of the leading causes of disability and chronic pain. In SCI-induced pathology, homeostasis of the nitric oxide (NO) metabolome is lost. Major NO metabolites such as S-nitrosoglutathione (GSNO) and peroxynitrite are reported to play pivotal roles in regulating the activities of key cysteine proteases, calpains. While peroxynitrite (a metabolite of NO and superoxide) up regulates the activities of calpains leading to neurodegeneration, GSNO (a metabolite of NO and glutathione) down regulates the activities of calpains leading to neuroprotection. In this study, effect of GSNO on locomotor function and pain threshold and their relationship with the levels of peroxynitrite and the activity of calpain in the injured spinal cord were investigated using a 2-week rat model of contusion SCI.
</p></sec><sec><title>Results</title><p id="Par2">SCI animals were initially treated with GSNO at 2&#160;h after the injury followed by a once daily dose of GSNO for 14&#160;days. Locomotor function was evaluated by &#8220;Basso Beattie and Bresnahan (BBB) locomotor rating scale&#8221; and pain by mechanical allodynia. Peroxynitrite level, as expression of 3-nitrotyrosine (3-NT), calpain activity, as the degradation products of calpain substrate alpha II spectrin, and nNOS activity, as the expression phospho nNOS, were measured by western blot analysis. Treatment with GSNO improved locomotor function and mitigated pain. The treatment also reduced the levels of peroxynitrite (3-NT) and decreased activity of calpains. Reduced levels of peroxynitrite resulted from the GSNO-mediated inhibition of aberrant activity of neuronal nitric oxide synthase (nNOS).</p></sec><sec><title>Conclusions</title><p id="Par3">The data indicates that higher levels of 3-NT and aberrant activities of nNOS and calpains correlated with SCI pathology and functional deficits. Treatment with GSNO improved locomotor function and mitigated mechanical allodynia acutely post-injury. Because GSNO shows potential to ameliorate experimental SCI, we discuss implications for GSNO therapy in clinical SCI research.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>BBB</kwd><kwd>Calpains</kwd><kwd>GSNO</kwd><kwd>nNOS</kwd><kwd>Peroxynitrite</kwd><kwd>SCI</kwd><kwd>Pain</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000738</institution-id><institution>U.S. Department of Veterans Affairs</institution></institution-wrap></funding-source><award-id>BX003401</award-id><award-id>RX002090</award-id><principal-award-recipient><name><surname>Singh</surname><given-names>Inderjit</given-names></name><name><surname>Singh</surname><given-names>Avtar K.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>South Carolina Spinal Cord Injury Research Fund Board</institution></funding-source><award-id>SCIRF2017-I01</award-id><principal-award-recipient><name><surname>Khan</surname><given-names>Mushfiquddin</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par15">Spinal cord injury (SCI) results in locomotor deficits and pain due to the production of noxious metabolites which are held responsible for profound neurodegeneration [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. SCI is a major medical and socio-economic problem, and the rate of SCI is increasing every year [<xref ref-type="bibr" rid="CR3">3</xref>]. The incidence of SCI is highest among young adults due to motor vehicle accidents, violence and sports accidents [<xref ref-type="bibr" rid="CR4">4</xref>]. Other than critical care management, no current FDA-approved drug therapy exists for traumatic SCI [<xref ref-type="bibr" rid="CR1">1</xref>]. Several pharmacological therapies, including methylprednisolone, have been evaluated time and again in SCI [<xref ref-type="bibr" rid="CR2">2</xref>] without clinical success. SCI is divided into two distinct types of injury: primary and secondary. Primary (immediate phase after SCI) injury includes physical damage as a direct result of the traumatic event. It cannot be reversed. Secondary injury follows the initial physical insult, resulting from mechanistic crosstalk between and among several deleterious pathways, including redox and excitotoxicity [<xref ref-type="bibr" rid="CR1">1</xref>]. Secondary injury is therefore amenable to reversal and treatment. A critical examination of injury mechanisms shows a disturbed nitric oxide (NO) metabolome [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. We hypothesize this metabolome to be responsible for the production of neuronal nitric oxide synthase (nNOS)-dependent deleterious peroxynitrite. As a consequence, much less NO is available for S-nitrosoglutathione (GSNO) biosynthesis and thus GSNO-mediated regulation of enzymatic activities is lost. Reduced NO bioavailability and the consequent decrease in GSNO levels are associated with chronic neurovascular injuries, and exogenous GSNO supplementation is reported to ameliorate CNS injuries [<xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. Therefore, the objective of this study was to investigate the efficacy of GSNO for functional recovery and its role in regulation of the nNOS/calpain system in a rat model of contusion SCI.
</p><p id="Par16">GSNO is an endogenous molecule of the human body, produced mainly in NOS expressing cells by the reaction of NO with glutathione (GSH) in the presence of oxygen [<xref ref-type="bibr" rid="CR12">12</xref>]. GSNO&#8217;s biosynthesis is also influenced by altered redox [<xref ref-type="bibr" rid="CR13">13</xref>]. It is present in the brain and other organs [<xref ref-type="bibr" rid="CR14">14</xref>]. GSNO reductase (GSNOR) is the major GSNO-degrading enzyme and thus GSNOR knock out mice store GSNO in excess [<xref ref-type="bibr" rid="CR15">15</xref>]. GSNOR degrades GSNO to ammonia and oxidized glutathione (GSSG) without releasing free NO [<xref ref-type="bibr" rid="CR16">16</xref>], indicating that the NO moiety of GSNO is not recycled by the enzymatic activity of GSNOR. GSNO is directly involved in cell signaling via S-nitrosylation of target proteins, including calpains, NF-&#954;B, STAT3, neuronal NOS (nNOS) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>]. Several studies showing the efficacy of GSNO in human diseases have been listed by Hornyak et al. [<xref ref-type="bibr" rid="CR22">22</xref>]. None of the studies reported significant side effects in humans associated with the use of exogenous GSNO. In animal studies, GSNO protects against cardiac ischemic injury [<xref ref-type="bibr" rid="CR23">23</xref>], indicating the therapeutic potential of GSNO-mediated S-nitrosylation mechanism [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. S-nitrosylation of PTEN (a lipid phosphatase) has been shown to inhibit its activity, leading to the activation of Akt and thus the stimulation of neurorepair process in an animal model of stroke [<xref ref-type="bibr" rid="CR25">25</xref>]. The Akt activation has been shown to be associated with stabilization of hypoxia-inducible factor-1 alpha (HIF-1&#945;), which, in turn, induces the expression vascular endothelial growth factor (VEGF) leading to therapeutic angiogenesis/neurogenesis and consequent recovery of function [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par17">In spite of the significant role of GSNO in cellular functions, neither GSNO nor its S-nitrosylation mechanism has been investigated for anti-neurodegenerative efficacy in SCI. Decreased synthesis of GSNO due to reduced levels of either GSH [<xref ref-type="bibr" rid="CR19">19</xref>] or NO [<xref ref-type="bibr" rid="CR27">27</xref>] or both in SCI, combined with increased degradation of GSNO by inflammation-induced enzyme activity of GSNO reductase (GSNOR) [<xref ref-type="bibr" rid="CR24">24</xref>], will likely contribute to the reduced levels of GSNO in SCI. Deficient S-nitrosylation is considered to be a general neurodegenerative mechanism [<xref ref-type="bibr" rid="CR28">28</xref>&#8211;<xref ref-type="bibr" rid="CR30">30</xref>]. Via S-nitrosylation, GSNO protects against neurodegeneration by targeting multiple signaling pathways, including anti-inflammatory, anti-oxidant and vascular effects [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR31">31</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref>]. GSNO also stimulates production of neurotrophic factors [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] and induces neuroregeneration [<xref ref-type="bibr" rid="CR35">35</xref>]. On the other hand, peroxynitrite is formed by an instantaneous diffusion limited reaction between NO and superoxide under oxidative conditions. This reaction not only reduces NO bioavailability but also increases peroxynitrite-mediated tissue/cell damage. Peroxynitrite causes a sustained activation of calpains [<xref ref-type="bibr" rid="CR36">36</xref>], leading to neurodegeneration and functional deficits [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. In SCI, the observed increased 3-nitrotyrosine (3NT) levels, a peroxynitrite adduct of tyrosine residue, in the injured cord [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] suggest its pathological role in SCI. We observed that GSNO treatment of SCI decreased the levels of peroxynitrite via inhibition of nNOS activation, which paralleled with decreased calpain activity and improved Basso Beattie and Bresnahan (BBB) locomotor rating scale scores as well as the threshold for mechanical allodynia out to 2&#160;weeks post-injury.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Experimental procedure</title><sec id="Sec4"><title>Reagents</title><p id="Par18">GSNO (Item#: GSNO-100) was purchased from World Precision Instruments (Sarasota, FL, USA). All other chemicals and reagents used were purchased from Sigma-Aldrich (St. Louis, MO), unless stated otherwise.</p></sec><sec id="Sec5"><title>Animals</title><p id="Par19">Animals were young adult male Sprague&#8211;Dawley (SD) rats, obtained from Harlan Laboratory (Wilmington, MA), weighing 250&#8211;300&#160;g at the time of surgery. All animals received humane care in compliance with the Medical University of South Carolina&#8217;s (MUSC) guidance and the National Research Council&#8217;s criteria for humane care. Animal procedures were approved by the institutional animal care and use committee (IACUC) of MUSC.</p></sec><sec id="Sec6"><title>Experimental groups, drugs and dose</title><p id="Par20">The animals (n&#8201;=&#8201;21) were randomly divided into three groups: (1) SCI animals treated with vehicle (SCI; n&#8201;=&#8201;7), (2) SCI animals treated with GSNO (GSNO; n&#8201;=&#8201;7), and (3) sham-operated treated with vehicle (Sham; n&#8201;=&#8201;7). In the SCI&#8201;+&#8201;GSNO treatment group, the rats were administered freshly prepared GSNO (0.05&#160;mg/kg body weight), which was dissolved in sterile saline (~&#8201;25&#160;&#956;l) and administered iv at 2&#160;h after SCI. The dose of GSNO treatment was based on our previously reported dose response curve study, using 10&#160;&#181;g to 100&#160;&#181;g/kg body weight in a rat model of SCI and TBI [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. The dose 50&#160;&#181;g/kg was found most effective in reducing contusion volume measured at 7&#160;days after TBI [<xref ref-type="bibr" rid="CR39">39</xref>]. Tests on uninjured sham rats did not produce alterations in physiologic parameters (blood pressure, heart rate, and body temperature) measured at 1&#160;h following GSNO treatment [<xref ref-type="bibr" rid="CR39">39</xref>]. Details of a GSNO study on physiologic parameters in rats have been previously described [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec7"><title>Rat model of contusion SCI</title><p id="Par21">Surgical anesthesia was induced by ketamine (90&#160;mg/kg body weight) and xylazine (10&#160;mg/kg body weight) administered intraperitoneally (ip). The animal was then placed onto a heated pad, and core body temperature was maintained at 37.0&#8201;&#177;&#8201;1&#160;&#176;C. The animals were secured in a stereotaxic frame. A dab of sterile ophthalmic ointment was placed on each eye to compensate for the decrease in lacrimation during anesthesia. SCI at the T9-T10 level was produced on the exposed spinal cord following a dorsal median incision and laminectomy. SCI was induced using a computer controlled impactor device described by Dr. Bilgen [<xref ref-type="bibr" rid="CR40">40</xref>] and used in our studies [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>] under aseptic conditions. SCI was performed with 2&#160;mm tissue deformation and an impact velocity of 1.5&#160;m/s and contusion time 85&#160;ms. These parameters and conditions produced reproducible moderate spinal cord injury as described in our publications [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Sham animals had the same procedures, with the exception of the impact. The impact tip was wiped clean with sterile alcohol after each impact and cleaned/disinfected further with cidex after surgery. During impact, body temperature was maintained at 37&#160;&#176;C by a heating pad. Immediately after injury, the incision was closed with nylon suture, and 2% lidocaine jelly was applied to the lesion site to minimize any possible discomfort. Post-surgical care: the bladders of all animals were expressed two to three times per day initially and later as needed. The body weight and humane endpoints were regularly monitored. Analgesic treatment was avoided after surgery because pain is also a target of this investigation. Antibiotic treatment was used in the event of persistent infection, which occurred rarely. The animals were sacrificed after the specified period of time with an overdose of ketamine/xylazine (90/10&#160;mg/kg body weight) administered ip, as approved by the IACUC of MUSC.</p></sec><sec id="Sec8"><title>Evaluation of locomotor function</title><p id="Par22">All 7 rats were assessed at the indicated time points using the &#8220;Basso Beattie Bresnahan (BBB) locomotor rating scale&#8221; [<xref ref-type="bibr" rid="CR43">43</xref>]. The BBB rating was described with a 21-point scale to measure hind limb function at various time points after injury. The scale assesses several different categories, including limb movement and tail position [<xref ref-type="bibr" rid="CR43">43</xref>]. In our experiments, sham operated animals scored 21 (normal) on the BBB rating scale, whereas the SCI animals at day 0 had complete hind limb paralysis, thus scoring 0. Two investigators blinded to the experimental groups evaluated rats using the BBB scale as previously described from our laboratory [<xref ref-type="bibr" rid="CR7">7</xref>]. All rats in both SCI and GSNO (SCI&#8201;+&#8201;GSNO) had significantly lower BBB score evaluated on day 1 after SCI.</p></sec><sec id="Sec9"><title>Evaluation of mechanical allodynia</title><p id="Par23">Before the testing of mechanical allodynia, all rats were habituated for at least 2&#160;h on a metal mesh inside a <italic>von Frey</italic> plastic chamber. Nociception was measured by the paw pressure threshold using anesthesiometer (AM) (Ugo Basile, Italy), which applies a linearly increasing mechanical force to the dorsum of the rat&#8217;s hind paw. The test was performed as previously described from our laboratory [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. The nociceptive threshold was defined as the force in grams at which the rat withdrew its paw. Continuously increasing pressure was applied to the dorsal surface of the hind paws. The time the animal withdrew its paw was recorded. Three trials were made on each paw with 5&#160;min inter-test intervals. Testing was performed once per day until the end of the experiment. All rats in both SCI and GSNO (SCI&#8201;+&#8201;GSNO) developed significant pain when evaluated on day 3 after SCI.</p></sec><sec id="Sec10"><title>Western blot analysis</title><p id="Par24">At the endpoint, the animals were euthanized by decapitation under deep anesthesia and spinal cord was harvested for biochemical experiments. The spinal cords were snap frozen and stored at &#8722;&#8201;70&#160;&#176;C for subsequent assays, if needed.</p><p id="Par25">In the traumatic penumbra area (8&#160;mm segment consists of 2&#160;mm epicenter, 3&#160;mm caudal from epicenter, 3&#160;mm rostral from epicenter) from the injured cord tissue, western blot was performed as described earlier [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR46">46</xref>] using following antibodies. nNOS (Abcam Cat# ab1376, RRID:AB_300614, 0.2&#160;&#181;g/ml concentration), phospho nNOS Ser<sup>1417</sup>, equivalent to human Ser<sup>1412</sup> (Abcam Cat# ab90443, RRID:AB_2049208, 1.0&#160;&#181;g/ml concentration), 3-NT (Abcam Cat# ab7048, RRID:AB_305725, 0.1&#160;&#181;g/ml concentration), alpha II spectrin (Cell Signaling Cat# SC-46696, RRID:AB_671135, 0.2&#160;&#181;g/ml concentration) and &#946;-actin (Sigma-Aldrich Cat# A3853, RRID:AB_262137, 0.2&#160;&#181;g/ml concentration), followed by horseradish peroxidase-conjugated, goat anti-rabbit secondary antibody (Jackson ImmunoResearch Lab Cat# 111-035-045, RRID:AB_2337938, 1:4000 dilution). All non-phospho antibodies were diluted with 1XTBS-T with 2% non-fat dry milk. The pnNOS antibody was diluted using 1X TBS-T with 2% bovine serum albumin. Protein concentrations were determined using protein assay dye from Bio-Rad Laboratories (Hercules, CA). Twenty microgram protein was used for western analysis. Densitometry of protein expression was performed using a GS800 calibrated densitometer from Bio-Rad laboratories (Hercules, CA).</p></sec><sec id="Sec11"><title>Statistical evaluation</title><p id="Par26">Statistical analysis was performed using software Graph pad Prism 5.01 as described previously [<xref ref-type="bibr" rid="CR35">35</xref>]. The results are presented as the mean&#8201;&#177;&#8201;SD. Statistical significance was analyzed by one-way or two-way (ANOVA) with repeated measures with time, and Bonferroni post hoc test was used for multiple comparisons. A <italic>p</italic> value&#8201;&lt;&#8201;0.05 was considered significant.</p></sec></sec></sec><sec id="Sec12"><title>Results</title><sec id="Sec13"><title>Effects of exogenous GSNO treatment on locomotor function</title><p id="Par27">Evaluation of locomotor functions using BBB score in rats is the standard method [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>] to determine the efficacy of a preclinical/test drug in SCI. BBB scoring at 1, 3, 7 and 14&#160;days shows that SCI rats had significantly greater impaired motor function compared with sham animals (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). GSNO treatment significantly improved the recovery of locomotor function on day 14 (<italic>p</italic>&#8201;&lt;&#8201;0.001) compared with the SCI group animals (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The data showed slow but steady recovery with time, supporting the efficacy of GSNO for functional improvement following SCI.<fig id="Fig1"><label>Fig.&#160;1</label><caption><p>Effect of GSNO on locomotor function. Studies on locomotor function using BBB locomotor rating scale were performed at days 1, 3, 7 and 14. BBB rating was evaluated by a blinded observer. Score of 21 (BBB) was assigned to sham animals displaying coordinated gait, consistent toe clearance, lifted tail, steady trunk, and parallel paw position throughout their stance. Data are presented as mean&#8201;&#177;&#8201;standard deviation (n&#8201;=&#8201;7). <sup>+</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 versus GSNO day 1, 3, <sup>++</sup><italic>p</italic>&#8201;&lt;&#8201;0.01 versus GSNO day 1, 3, *<italic>p</italic>&#8201;&lt;&#8201;0.05 versus SCI day 14. <italic>NS</italic> non-significant</p></caption><graphic xlink:href="12868_2018_450_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec14"><title>Effects of exogenous GSNO treatment on neuropathic pain</title><p id="Par28">Chronic neuropathic pain is associated with SCI, with substantial impact on quality of life in humans [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Significant mechanical sensitivity differences were observed in both SCI and GSNO-treated SCI (GSNO) groups after SCI compared with the sham group. From day 7 onward, the GSNO group had a significantly improved/increased mechanical withdrawal latency compared with the SCI group (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>), indicating an improved pain threshold.<fig id="Fig2"><label>Fig.&#160;2</label><caption><p>Effect of GSNO on nociception. Pain threshold was measured with aesthesiometer (AM) for 14&#160;days following SCI. GSNO treatment significantly improved the hyperalgesia associated with SCI. Data are presented as mean&#8201;&#177;&#8201;standard deviation (n&#8201;=&#8201;7). <sup>+++</sup><italic>p</italic>&#8201;&lt;&#8201;0.001; <sup>++</sup><italic>p</italic>&#8201;&lt;&#8201;0.01; <sup>+</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 versus Sham, **<italic>p</italic>&#8201;&lt;&#8201;0.01; *<italic>p</italic>&#8201;&lt;&#8201;0.05 versus SCI</p></caption><graphic xlink:href="12868_2018_450_Fig2_HTML" id="MO2"/></fig>
</p></sec><sec id="Sec15"><title>Effects of exogenous GSNO treatment on the levels of peroxynitrite (3-NT) and the activation of nNOS (Ser<sup>1412</sup> phosphorylation)</title><p id="Par29">We and others have identified neuronal peroxynitrite as a major causative factor in SCI pathology [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR51">51</xref>], and decreasing peroxynitrite levels by GSNO is a major mechanism in GSNO-mediated neuroprotection and functional recovery in TBI [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Neuronal peroxynitrite is produced by the aberrant activity of nNOS after CNS trauma. Peroxynitrite levels, measured by the expression of 3-NT, were significantly higher in the SCI compared with the sham group (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>a, b, <italic>p</italic>&#8201;&lt;&#8201;0.001). Treatment with GSNO significantly decreased these elevations (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>a, b). The levels of 3-NT in SCI correlated well with the activation of nNOS (increased phosphorylation at Ser<sup>1412</sup>) compared with the sham group (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>c, d, <italic>p</italic>&#8201;&lt;&#8201;0.001). GSNO treatment of SCI significantly down regulated nNOS activation compared with SCI (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>c, d, <italic>p</italic>&#8201;&lt;&#8201;0.001). The parallel between the levels of 3-NT and the activation of nNOS (pnNOS) indicates that SCI-induced peroxynitrite may have originated mainly from nNOS, and the activity of nNOS is regulated/inhibited by GSNO, likely via S-nitrosylation.<fig id="Fig3"><label>Fig.&#160;3</label><caption><p>Immunoblots of 3-NT, nNOS, and phosphorylated nNOS (Ser<sup>1412</sup>) in the traumatic penumbra (immediately after epicenter) at 14&#160;days after SCI. SCI increased the expression levels of 3-NT (<bold>a</bold>), its densitometry (<bold>b</bold>), phosphorylated nNOS (Ser<sup>1412</sup>) (<bold>c</bold>), and its densitometry (<bold>d</bold>). GSNO treatment of SCI decreased expression levels (<bold>a</bold>&#8211;<bold>d</bold>). Expression of nNOS remained unchanged in all three groups (<bold>c</bold>). Data are presented as mean&#8201;&#177;&#8201;standard deviation (n&#8201;=&#8201;7). <sup>+++</sup><italic>p</italic>&#8201;&lt;&#8201;0.001 versus Sham and ***<italic>p</italic>&#8201;&lt;&#8201;0.001 versus SCI</p></caption><graphic xlink:href="12868_2018_450_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec16"><title>Effects of exogenous GSNO treatment on the activity of calpains measured as &#945;-II-spectrin breakdown products</title><p id="Par30">Neuronal alpha-II-spectrin (280&#160;kDa) is one of the major substrates of calpains [<xref ref-type="bibr" rid="CR52">52</xref>]. The calpain-specific alpha II spectrin breakdown product (SBDP)145&#160;kDa fragment is used as a marker of calpain activity [<xref ref-type="bibr" rid="CR53">53</xref>]. The band at 150&#160;kDa is also a cleavage product of calpain activity; however, it is not specific to calpain activity [<xref ref-type="bibr" rid="CR54">54</xref>]. The intensity of the 150&#160;kDa band was significantly less than the 145&#160;kDa band. Calpain activity, measured via &#945;-II-spectrin breakdown product (SBDP) 145&#160;kDa, was significantly higher (<italic>p</italic>&#8201;&lt;&#8201;0.001) in the SCI group compared with the sham (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>a, b). GSNO treatment of SCI significantly (<italic>p</italic>&#8201;&lt;&#8201;0.001) decreased the levels of SBDP 145&#160;kDa, indicating that GSNO decreased the activity of calpains (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>a, b). The activity of calpains (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>) correlated well with levels of 3-NT and the activation of nNOS, as shown in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>.<fig id="Fig4"><label>Fig.&#160;4</label><caption><p>Immunoblots of &#945;-II-spectrin in the traumatic penumbra at 14&#160;days after SCI. SCI increased &#945;-II-spectrin breakdown products (SBDP 145&#160;kDa, indicated by red arrow) (<bold>a</bold>) and its densitometry (<bold>b</bold>). GSNO treatment of SCI decreased SBDP 145&#160;kDa (<bold>a</bold>, <bold>b</bold>). Data are presented as mean&#8201;&#177;&#8201;standard deviation (n&#8201;=&#8201;7). <sup>+++</sup><italic>p</italic>&#8201;&lt;&#8201;0.001 versus Sham, ***<italic>p</italic>&#8201;&lt;&#8201;0.001 versus SCI</p></caption><graphic xlink:href="12868_2018_450_Fig4_HTML" id="MO4"/></fig>
</p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par31">This is a preliminary mechanism-based study showing that SCI-induced functional deficits (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>), and neuropathic pain (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) paralleled aberrant activation of nNOS, increased levels of peroxynitrite (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>) and high activity of calpains (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>) in a 2-week rat model of contusion SCI. The study further shows the therapeutic efficacy of GSNO. It improved functional deficits (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>) and increased the pain threshold (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) by inhibiting the activities of both nNOS (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>) and calpains (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>) and reducing the levels of injurious peroxynitrite (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).</p><p id="Par32">Locomotor function deficits and pain are two major consequences intrinsic to SCI [<xref ref-type="bibr" rid="CR49">49</xref>]. Deleterious metabolites, formed by the aberrant activities of otherwise regulatory enzymes such as nNOS, are primarily responsible for producing potent oxidizing/neurodegenerating agents, such as peroxynitrite, in neurons. Excessive accumulation of neuronal peroxynitrite is implicated in neuronal cell death and subsequent neurodegeneration [<xref ref-type="bibr" rid="CR55">55</xref>]. In fact, scavenging peroxynitrite using peroxynitrite decomposition catalysts such as FeTPPS has been reported to ameliorate SCI [<xref ref-type="bibr" rid="CR56">56</xref>], supporting this direct deleterious role of peroxynitrite. Inhibition of nNOS activity following SCI [<xref ref-type="bibr" rid="CR57">57</xref>] has also been shown to provide neuroprotection, and nNOS KO mice show improved recovery after SCI [<xref ref-type="bibr" rid="CR58">58</xref>], indicating a deleterious role of nNOS activity in SCI. An nNOS-based therapy for SCI therefore offers a logical approach. Reversible down regulation of nNOS activity, such as via-S-nitrosylation, is preferred because it maintains the required physiological activity of nNOS. The roles of other NOS enzymes (inducible and endothelial) in the chronic phase pathology, such as in neurodegeneration and pain, is not clear [<xref ref-type="bibr" rid="CR59">59</xref>]. Peroxynitrite produced in neurons is a product of an instantaneous reaction between nNOS-derived NO and superoxide. Because NO is used for the formation of peroxynitrite (3-NT), the biosynthesis of GSNO, a product of a slow reaction between NO and GSH, and GSNO-mediated regulatory mechanisms are derailed. Because deleterious nNOS activity is down regulated by a GSNO-mediated S-nitrosylation mechanism [<xref ref-type="bibr" rid="CR60">60</xref>], reduced NO/GSNO levels contribute to nNOS-dependent neurodegeneration and pain SCI pathology. Such a derailed NO/GSNO metabolism in SCI may also be responsible for functional deficits. Therefore, we tested the hypothesis that GSNO reduces the levels of peroxynitrite, inhibits the activity of nNOS, and improves behavioral function and cellular plasticity in young adult male rats.</p><p id="Par33">Pain is one of the major issues in SCI for obvious reasons but also because it impairs recovery after SCI [<xref ref-type="bibr" rid="CR61">61</xref>]. Both inflammatory and neuropathic pain (caused by a lesion or disease of somatosensory function) are present in the majority of SCI patients [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Due to the lack of mechanistic understanding of pain, satisfactory pain-management therapy of SCI is not yet available. We observed that the GSNO treatment significantly increased the pain threshold and reduced calpain activity after 2&#160;weeks of SCI (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>), indicating that GSNO possesses an analgesic property in addition to improving functional deficits (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Furthermore, significant increases in tissue peroxynitrite levels (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>) correlated well with calpain-mediated cytoskeleton degradation (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>), indicating peroxynitrite&#8217;s contribution to neurodegeneration. Recently, we have shown that the activity of calpains is upregulated by peroxynitrite whereas GSNO, via S-nitrosylation, inhibits the activity of calpains in TBI [<xref ref-type="bibr" rid="CR8">8</xref>], indicating a similar role of peroxynitrite versus GSNO in this SCI study. Peroxynitrite originating from nNOS [<xref ref-type="bibr" rid="CR63">63</xref>] and NMDA receptor activity [<xref ref-type="bibr" rid="CR64">64</xref>] is also recognized among the prominent causes of neuropathic pain following nerve injury. GSNO, likely via S-nitrosylation, down regulates the activity of nNOS, thus reducing the levels of peroxynitrite and its associated pain. Decreased levels of peroxynitrite in brains and improved neurological functions have also been shown after GSNO treatment in rat models of stroke and TBI [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR51">51</xref>], indicating that the mechanism of S-nitrosylation invokes anti-neurodegeneration and anti-pain activities in CNS trauma. These observations establish the therapeutic potential of GSNO-mediated mechanisms in simultaneously treating neurodegeneration and neuropathic pain following SCI.</p><p id="Par34">Inflammation is another significant component of SCI, contributing to neurodegeneration and pain. Interestingly, GSNO-mediated mechanisms are also shown to down regulate the expression of pro-inflammatory cytokines and NF-&#954;B [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], as well as the activation of STAT3 [<xref ref-type="bibr" rid="CR20">20</xref>]. These actions contribute to the reduction of inflammation-mediated neurodegeneration and pain. As an alternative mechanism to alleviate pain in SCI, IL-10 has been shown to be a potent anti-neuropathic pain molecule [<xref ref-type="bibr" rid="CR65">65</xref>&#8211;<xref ref-type="bibr" rid="CR67">67</xref>], and GSNO-mediated mechanisms are reported to upregulate the levels of IL-10 [<xref ref-type="bibr" rid="CR68">68</xref>] as well as to reduce pain in a rat model of cauda equine compression [<xref ref-type="bibr" rid="CR44">44</xref>]. We add one caveat that excessive accumulation of GSNO, as observed in GSNOR knock out mice, creates altered redox pathology, leading to sensitization to pain [<xref ref-type="bibr" rid="CR15">15</xref>] and thus rendering GSNOR knock out mice &#8216;not suitable&#8217; for pain related studies. A critical balance of NO/GSNO versus peroxynitrite is requisite to maintain the homeostasis of the NO metabolome, ameliorating SCI pathology. Low dose exogenous supplementation of GSNO seems to be an ideal approach to improve pain threshold and to provide neuroprotection. One advantage of using GSNO supplementation is that GSNO-mediated regulatory mechanisms are reversible, and thus the physiological levels of activity of targeted enzymes can be maintained. The improved BBB score (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>) and increased pain threshold (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>) reported here support the efficacy of GSNO in ameliorating SCI and provide a rationale to further investigate GSNO therapy in SCI. <italic>Limitations</italic> the most affected population from SCI is young adult males. Therefore, we used young adult male animals in this preliminary study; however, the exclusion of female rats demands further testing in these populations. We are also aware that a 2-week SCI study is relatively short to sufficiently characterize the injury course. Moreover, biochemical studies of the early acute phase are needed. Therefore, in follow-up study, the efficacy of GSNO therapy and the cause-and-effect relationship between GSNO and peroxynitrite/calpain system will be investigated for both acute and longer chronic periods of time, using both male and female young adult animals.</p></sec><sec id="Sec18"><title>Conclusions</title><p id="Par35">Under SCI pathology, superoxide reacts with NO and this reaction produces a large amount of injurious peroxynitrite. Increased levels of peroxynitrite cause an upregulation of calpain activity and thus neuronal cytoskeleton degradation. Peroxynitrite is also recognized as a mediator of pain. Under such pathological conditions, S-nitrosylation-mediated biological regulation (inhibition) of the activity of nNOS and calpain is lost due to its reduced bioavailability, and thus levels of NO/GSNO. Replenishment of exogenous GSNO was found to inhibit the activation of nNOS, thus blocking the production of peroxynitrite and reducing the activity of calpains, leading to improved locomotor function and decreased mechanical allodynia acutely post-injury in SCI animals. Furthermore GSNO&#8217;s administration to humans is not associated with adverse effects [<xref ref-type="bibr" rid="CR22">22</xref>]. Therefore, testing the efficacy of exogenous GSNO in humans may lead to an SCI therapy of clinical relevance.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BBB</term><def><p id="Par4">Basso Beattie and Bresnahan</p></def></def-item><def-item><term>GSNO</term><def><p id="Par5">S-nitrosoglutathione</p></def></def-item><def-item><term>HIF-1&#945;</term><def><p id="Par6">hypoxia-inducible factor-1 alpha</p></def></def-item><def-item><term>IHC</term><def><p id="Par7">immunohistochemistry</p></def></def-item><def-item><term>nNOS</term><def><p id="Par8">neuronal nitric oxide synthase</p></def></def-item><def-item><term>NO</term><def><p id="Par9">nitric oxide</p></def></def-item><def-item><term>3-NT</term><def><p id="Par10">3-nitrotyrosine</p></def></def-item><def-item><term>PTEN</term><def><p id="Par11">phosphatase with sequence homology to tensin</p></def></def-item><def-item><term>SCI</term><def><p id="Par12">spinal cord injury</p></def></def-item><def-item><term>Sham</term><def><p id="Par13">sham-operated animals</p></def></def-item><def-item><term>VEGF</term><def><p id="Par14">vascular endothelial growth factor</p></def></def-item></def-list></glossary><ack><title>Authors&#8217; contributions</title><p>This study is based on an original idea of MK, AKS and IS. MK and AKS wrote the manuscript and all authors reviewed the manuscript. TS Dhammu carried out animal and biochemical studies. MK, AKS, TS Dhammu, and IS critically examined biochemical studies. TS Dhammu performed locomotor behavior and neuropathic pain studies. MK performed statistical analysis. All authors read and approved the final manuscript.
</p><sec id="FPar1"><title>Acknowledgements</title><p id="Par36">We would like to thank Ms. Danielle Lowe, a medical graduate student from the MUSC, for assistance with statistical analysis. We acknowledge Dr. Tom Smith from the MUSC Writing Center for his valuable editing of the manuscript.</p></sec><sec id="FPar2"><title>Competing interests</title><p id="Par37">The authors declare that they have no competing interests.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p id="Par38">Data included in this study are stored in our laboratory. Materials will be distributed, if requested by other investigators.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par39">Not applicable.</p></sec><sec id="FPar5"><title>Ethical approval and consent to participate</title><p id="Par40">All animals received humane care in compliance with the Medical University of South Carolina&#8217;s (MUSC) guidance and the National Research Council&#8217;s criteria for humane care. Animal procedures were approved by the institutional animal care and use committee (IACUC) of MUSC.</p></sec><sec id="FPar6"><title>Funding</title><p id="Par41">This study was made possible by the VA Office of Research and Development (VA merit awards; BX003401 and RX002090) and the South Carolina Spinal Cord Injury Research Fund (Grant# SCIRF2017 I-01). This work was also supported by the NIH, Grants C06 RR018823 and No. C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources.</p></sec><sec id="FPar7"><title>Publisher's Note</title><p id="Par42">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>AM</given-names></name><name><surname>Khazaei</surname><given-names>M</given-names></name><name><surname>Fehlings</surname><given-names>MG</given-names></name></person-group><article-title>Translating mechanisms of neuroprotection, regeneration, and repair to treatment of spinal cord injury</article-title><source>Prog Brain Res</source><year>2015</year><volume>218</volume><fpage>15</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/bs.pbr.2014.12.007</pub-id><pub-id pub-id-type="pmid">25890131</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varma</surname><given-names>AK</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>G</given-names></name><name><surname>Barry</surname><given-names>J</given-names></name><name><surname>Vertegel</surname><given-names>AA</given-names></name><name><surname>Ray</surname><given-names>SK</given-names></name><name><surname>Banik</surname><given-names>NL</given-names></name></person-group><article-title>Spinal cord injury: a review of current therapy, future treatments, and basic science frontiers</article-title><source>Neurochem Res</source><year>2013</year><volume>38</volume><issue>5</issue><fpage>895</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1007/s11064-013-0991-6</pub-id><pub-id pub-id-type="pmid">23462880</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furlan</surname><given-names>JC</given-names></name><name><surname>Sakakibara</surname><given-names>BM</given-names></name><name><surname>Miller</surname><given-names>WC</given-names></name><name><surname>Krassioukov</surname><given-names>AV</given-names></name></person-group><article-title>Global incidence and prevalence of traumatic spinal cord injury</article-title><source>Can J Neurol Sci</source><year>2013</year><volume>40</volume><issue>4</issue><fpage>456</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1017/S0317167100014530</pub-id><pub-id pub-id-type="pmid">23786727</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvarajah</surname><given-names>S</given-names></name><name><surname>Hammond</surname><given-names>ER</given-names></name><name><surname>Haider</surname><given-names>AH</given-names></name><name><surname>Abularrage</surname><given-names>CJ</given-names></name><name><surname>Becker</surname><given-names>D</given-names></name><name><surname>Dhiman</surname><given-names>N</given-names></name><name><surname>Hyder</surname><given-names>O</given-names></name><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Black</surname><given-names>JH</given-names><suffix>3rd</suffix></name><name><surname>Schneider</surname><given-names>EB</given-names></name></person-group><article-title>The burden of acute traumatic spinal cord injury among adults in the united states: an update</article-title><source>J Neurotrauma</source><year>2014</year><volume>31</volume><issue>3</issue><fpage>228</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1089/neu.2013.3098</pub-id><pub-id pub-id-type="pmid">24138672</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tardivo</surname><given-names>V</given-names></name><name><surname>Crobeddu</surname><given-names>E</given-names></name><name><surname>Pilloni</surname><given-names>G</given-names></name><name><surname>Fontanella</surname><given-names>M</given-names></name><name><surname>Spena</surname><given-names>G</given-names></name><name><surname>Panciani</surname><given-names>PP</given-names></name><name><surname>Berjano</surname><given-names>P</given-names></name><name><surname>Ajello</surname><given-names>M</given-names></name><name><surname>Bozzaro</surname><given-names>M</given-names></name><name><surname>Agnoletti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Say &#8220;no&#8221; to spinal cord injury: is nitric oxide an option for therapeutic strategies?</article-title><source>Int J Neurosci</source><year>2015</year><volume>125</volume><issue>2</issue><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.3109/00207454.2014.908877</pub-id><pub-id pub-id-type="pmid">24697508</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Ling</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>The role of reactive nitrogen species in secondary spinal cord injury: formation of nitric oxide, peroxynitrite, and nitrated protein</article-title><source>J Neurochem</source><year>2000</year><volume>75</volume><issue>5</issue><fpage>2144</fpage><lpage>2154</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0752144.x</pub-id><pub-id pub-id-type="pmid">11032904</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>PC</given-names></name><name><surname>Shunmugavel</surname><given-names>A</given-names></name><name><surname>Sayed</surname><given-names>HE</given-names></name><name><surname>Desouki</surname><given-names>MM</given-names></name><name><surname>Nguyen</surname><given-names>SA</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Bilgen</surname><given-names>M</given-names></name></person-group><article-title>Preclinical use of longitudinal MRI for screening the efficacy of s-nitrosoglutathione in treating spinal cord injury</article-title><source>J Magn Reson Imaging</source><year>2011</year><volume>33</volume><issue>6</issue><fpage>1301</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1002/jmri.22574</pub-id><pub-id pub-id-type="pmid">21590998</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Dhammu</surname><given-names>TS</given-names></name><name><surname>Matsuda</surname><given-names>F</given-names></name><name><surname>Annamalai</surname><given-names>B</given-names></name><name><surname>Dhindsa</surname><given-names>TS</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name></person-group><article-title>Targeting the nNOS/peroxynitrite/calpain system to confer neuroprotection and aid functional recovery in a mouse model of TBI</article-title><source>Brain Res</source><year>2016</year><volume>1630</volume><fpage>159</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2015.11.015</pub-id><pub-id pub-id-type="pmid">26596859</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Dhammu</surname><given-names>TS</given-names></name><name><surname>Sakakima</surname><given-names>H</given-names></name><name><surname>Shunmugavel</surname><given-names>A</given-names></name><name><surname>Gilg</surname><given-names>AG</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name></person-group><article-title>The inhibitory effect of S-nitrosoglutathione on blood-brain barrier disruption and peroxynitrite formation in a rat model of experimental stroke</article-title><source>J Neurochem</source><year>2012</year><volume>123</volume><issue>Suppl 2</issue><fpage>86</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2012.07947.x</pub-id><pub-id pub-id-type="pmid">23050646</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Sakakima</surname><given-names>H</given-names></name><name><surname>Dhammu</surname><given-names>TS</given-names></name><name><surname>Shunmugavel</surname><given-names>A</given-names></name><name><surname>Im</surname><given-names>YB</given-names></name><name><surname>Gilg</surname><given-names>AG</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name></person-group><article-title>S-nitrosoglutathione reduces oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats</article-title><source>J Neuroinflammation</source><year>2011</year><volume>8</volume><issue>1</issue><fpage>78</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-8-78</pub-id><pub-id pub-id-type="pmid">21733162</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakakima</surname><given-names>H</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Dhammu</surname><given-names>TS</given-names></name><name><surname>Shunmugavel</surname><given-names>A</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name></person-group><article-title>Stimulation of functional recovery via the mechanisms of neurorepair by S-nitrosoglutathione and motor exercise in a rat model of transient cerebral ischemia and reperfusion</article-title><source>Restor Neurol Neurosci</source><year>2012</year><volume>30</volume><issue>5</issue><fpage>383</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">22717646</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>SP</given-names></name><name><surname>Wishnok</surname><given-names>JS</given-names></name><name><surname>Keshive</surname><given-names>M</given-names></name><name><surname>Deen</surname><given-names>WM</given-names></name><name><surname>Tannenbaum</surname><given-names>SR</given-names></name></person-group><article-title>The chemistry of the S-nitrosoglutathione/glutathione system</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><issue>25</issue><fpage>14428</fpage><lpage>14433</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.25.14428</pub-id><pub-id pub-id-type="pmid">8962068</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jourd&#8217;heuil</surname><given-names>D</given-names></name><name><surname>Jourd&#8217;heuil</surname><given-names>FL</given-names></name><name><surname>Feelisch</surname><given-names>M</given-names></name></person-group><article-title>Oxidation and nitrosation of thiols at low micromolar exposure to nitric oxide. Evidence for a free radical mechanism</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><issue>18</issue><fpage>15720</fpage><lpage>15726</lpage><pub-id pub-id-type="doi">10.1074/jbc.M300203200</pub-id><pub-id pub-id-type="pmid">12595536</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kluge</surname><given-names>I</given-names></name><name><surname>Gutteck-Amsler</surname><given-names>U</given-names></name><name><surname>Zollinger</surname><given-names>M</given-names></name><name><surname>Do</surname><given-names>KQ</given-names></name></person-group><article-title>S-nitrosoglutathione in rat cerebellum: identification and quantification by liquid chromatography-mass spectrometry</article-title><source>J Neurochem</source><year>1997</year><volume>69</volume><issue>6</issue><fpage>2599</fpage><lpage>2607</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1997.69062599.x</pub-id><pub-id pub-id-type="pmid">9375694</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagna</surname><given-names>C</given-names></name><name><surname>Di Giacomo</surname><given-names>G</given-names></name><name><surname>Rizza</surname><given-names>S</given-names></name><name><surname>Cardaci</surname><given-names>S</given-names></name><name><surname>Ferraro</surname><given-names>E</given-names></name><name><surname>Grumati</surname><given-names>P</given-names></name><name><surname>De Zio</surname><given-names>D</given-names></name><name><surname>Maiani</surname><given-names>E</given-names></name><name><surname>Muscoli</surname><given-names>C</given-names></name><name><surname>Lauro</surname><given-names>F</given-names></name><etal/></person-group><article-title>S-nitrosoglutathione reductase deficiency-induced S-nitrosylation results in neuromuscular dysfunction</article-title><source>Antioxid Redox Signal</source><year>2014</year><volume>21</volume><issue>4</issue><fpage>570</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1089/ars.2013.5696</pub-id><pub-id pub-id-type="pmid">24684653</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname><given-names>SD</given-names></name><name><surname>Buxton</surname><given-names>ILO</given-names></name></person-group><article-title>The role of S-nitrosoglutathione reductase (GSNOR) in human disease and therapy</article-title><source>Crit Rev Biochem Mol Biol</source><year>2017</year><volume>52</volume><issue>3</issue><fpage>340</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1080/10409238.2017.1304353</pub-id><pub-id pub-id-type="pmid">28393572</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaffrey</surname><given-names>SR</given-names></name><name><surname>Erdjument-Bromage</surname><given-names>H</given-names></name><name><surname>Ferris</surname><given-names>CD</given-names></name><name><surname>Tempst</surname><given-names>P</given-names></name><name><surname>Snyder</surname><given-names>SH</given-names></name></person-group><article-title>Protein S-nitrosylation: a physiological signal for neuronal nitric oxide</article-title><source>Nat Cell Biol</source><year>2001</year><volume>3</volume><issue>2</issue><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/35055104</pub-id><pub-id pub-id-type="pmid">11175752</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Sekhon</surname><given-names>B</given-names></name><name><surname>Giri</surname><given-names>S</given-names></name><name><surname>Jatana</surname><given-names>M</given-names></name><name><surname>Gilg</surname><given-names>AG</given-names></name><name><surname>Ayasolla</surname><given-names>K</given-names></name><name><surname>Elango</surname><given-names>C</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name></person-group><article-title>S-nitrosoglutathione reduces inflammation and protects brain against focal cerebral ischemia in a rat model of experimental stroke</article-title><source>J Cereb Blood Flow Metab</source><year>2005</year><volume>25</volume><issue>2</issue><fpage>177</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600012</pub-id><pub-id pub-id-type="pmid">15647746</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Jatana</surname><given-names>M</given-names></name><name><surname>Elango</surname><given-names>C</given-names></name><name><surname>Paintlia</surname><given-names>AS</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name></person-group><article-title>Cerebrovascular protection by various nitric oxide donors in rats after experimental stroke</article-title><source>Nitric Oxide</source><year>2006</year><volume>15</volume><issue>2</issue><fpage>114</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.niox.2006.01.008</pub-id><pub-id pub-id-type="pmid">16524750</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Won</surname><given-names>JS</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Sharma</surname><given-names>AK</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name></person-group><article-title>STAT3 regulation by S-nitrosylation: implication for inflammatory disease</article-title><source>Antioxid Redox Signal</source><year>2014</year><volume>20</volume><issue>16</issue><fpage>2514</fpage><lpage>2527</lpage><pub-id pub-id-type="doi">10.1089/ars.2013.5223</pub-id><pub-id pub-id-type="pmid">24063605</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Dhammu</surname><given-names>TS</given-names></name><name><surname>Baarine</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Paintlia</surname><given-names>MK</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name></person-group><article-title>GSNO promotes functional recovery in experimental TBI by stabilizing HIF-1&#945;</article-title><source>Behav Brain Res</source><year>2018</year><volume>340</volume><fpage>63</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2016.10.037</pub-id><pub-id pub-id-type="pmid">27780722</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hornyak</surname><given-names>I</given-names></name><name><surname>Pankotai</surname><given-names>E</given-names></name><name><surname>Kiss</surname><given-names>L</given-names></name><name><surname>Lacza</surname><given-names>Z</given-names></name></person-group><article-title>Current developments in the therapeutic potential of S-nitrosoglutathione, an endogenous NO-donor molecule</article-title><source>Curr Pharm Biotechnol</source><year>2011</year><volume>12</volume><issue>9</issue><fpage>1368</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.2174/138920111798280983</pub-id><pub-id pub-id-type="pmid">21235457</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konorev</surname><given-names>EA</given-names></name><name><surname>Tarpey</surname><given-names>MM</given-names></name><name><surname>Joseph</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>JE</given-names></name><name><surname>Kalyanaraman</surname><given-names>B</given-names></name></person-group><article-title>S-nitrosoglutathione improves functional recovery in the isolated rat heart after cardioplegic ischemic arrest-evidence for a cardioprotective effect of nitric oxide</article-title><source>J Pharmacol Exp Ther</source><year>1995</year><volume>274</volume><issue>1</issue><fpage>200</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">7616400</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Que</surname><given-names>LG</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Whitehead</surname><given-names>GS</given-names></name><name><surname>Gavett</surname><given-names>SH</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><article-title>Protection from experimental asthma by an endogenous bronchodilator</article-title><source>Science</source><year>2005</year><volume>308</volume><issue>5728</issue><fpage>1618</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1126/science.1108228</pub-id><pub-id pub-id-type="pmid">15919956</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Numajiri</surname><given-names>N</given-names></name><name><surname>Takasawa</surname><given-names>K</given-names></name><name><surname>Nishiya</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Ohno</surname><given-names>K</given-names></name><name><surname>Hayakawa</surname><given-names>W</given-names></name><name><surname>Asada</surname><given-names>M</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name><name><surname>Azumi</surname><given-names>K</given-names></name><name><surname>Kamata</surname><given-names>H</given-names></name><etal/></person-group><article-title>On-off system for PI3-kinase-Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN)</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><issue>25</issue><fpage>10349</fpage><lpage>10354</lpage><pub-id pub-id-type="doi">10.1073/pnas.1103503108</pub-id><pub-id pub-id-type="pmid">21646525</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>XW</given-names></name><name><surname>Kuzuya</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Di</surname><given-names>Q</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Tsuzuki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Exercise training stimulates ischemia-induced neovascularization via phosphatidylinositol 3-kinase/Akt-dependent hypoxia-induced factor-1 alpha reactivation in mice of advanced age</article-title><source>Circulation</source><year>2010</year><volume>122</volume><issue>7</issue><fpage>707</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.909218</pub-id><pub-id pub-id-type="pmid">20679550</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malinski</surname><given-names>T</given-names></name><name><surname>Bailey</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>ZG</given-names></name><name><surname>Chopp</surname><given-names>M</given-names></name></person-group><article-title>Nitric oxide measured by a porphyrinic microsensor in rat brain after transient middle cerebral artery occlusion</article-title><source>J Cereb Blood Flow Metab</source><year>1993</year><volume>13</volume><issue>3</issue><fpage>355</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.1993.48</pub-id><pub-id pub-id-type="pmid">8478395</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schonhoff</surname><given-names>CM</given-names></name><name><surname>Matsuoka</surname><given-names>M</given-names></name><name><surname>Tummala</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>MA</given-names></name><name><surname>Estevez</surname><given-names>AG</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Kamaid</surname><given-names>A</given-names></name><name><surname>Ricart</surname><given-names>KC</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name><name><surname>Gaston</surname><given-names>B</given-names></name><etal/></person-group><article-title>S-nitrosothiol depletion in amyotrophic lateral sclerosis</article-title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><issue>7</issue><fpage>2404</fpage><lpage>2409</lpage><pub-id pub-id-type="doi">10.1073/pnas.0507243103</pub-id><pub-id pub-id-type="pmid">16461917</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>TC</given-names></name><name><surname>Chen</surname><given-names>SD</given-names></name><name><surname>Liu</surname><given-names>CC</given-names></name><name><surname>Yang</surname><given-names>DI</given-names></name></person-group><article-title>Protective effects of S-nitrosoglutathione against amyloid beta-peptide neurotoxicity</article-title><source>Free Radic Biol Med</source><year>2005</year><volume>38</volume><issue>7</issue><fpage>938</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2004.12.019</pub-id><pub-id pub-id-type="pmid">15749390</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauhala</surname><given-names>P</given-names></name><name><surname>Mohanakumar</surname><given-names>KP</given-names></name><name><surname>Sziraki</surname><given-names>I</given-names></name><name><surname>Lin</surname><given-names>AM</given-names></name><name><surname>Chiueh</surname><given-names>CC</given-names></name></person-group><article-title>S-nitrosothiols and nitric oxide, but not sodium nitroprusside, protect nigrostriatal dopamine neurons against iron-induced oxidative stress in vivo</article-title><source>Synapse</source><year>1996</year><volume>23</volume><issue>1</issue><fpage>58</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1098-2396(199605)23:1&lt;58::AID-SYN7&gt;3.0.CO;2-G</pub-id><pub-id pub-id-type="pmid">8723136</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>R</given-names></name><name><surname>Giri</surname><given-names>S</given-names></name><name><surname>Nath</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name></person-group><article-title>GSNO attenuates EAE disease by S-nitrosylation-mediated modulation of endothelial-monocyte interactions</article-title><source>Glia</source><year>2007</year><volume>55</volume><issue>1</issue><fpage>65</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1002/glia.20436</pub-id><pub-id pub-id-type="pmid">17019693</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiueh</surname><given-names>CC</given-names></name><name><surname>Rauhala</surname><given-names>P</given-names></name></person-group><article-title>The redox pathway of S-nitrosoglutathione, glutathione and nitric oxide in cell to neuron communications</article-title><source>Free Radic Res</source><year>1999</year><volume>31</volume><issue>6</issue><fpage>641</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1080/10715769900301211</pub-id><pub-id pub-id-type="pmid">10630687</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>DT</given-names></name><name><surname>Stamler</surname><given-names>JS</given-names></name></person-group><article-title>Regulation by S-nitrosylation of protein post-translational modification</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><issue>7</issue><fpage>4411</fpage><lpage>4418</lpage><pub-id pub-id-type="doi">10.1074/jbc.R111.285742</pub-id><pub-id pub-id-type="pmid">22147701</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paintlia</surname><given-names>MK</given-names></name><name><surname>Paintlia</surname><given-names>AS</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name></person-group><article-title>S-nitrosoglutathione induces ciliary neurotrophic factor expression in astrocytes, which has implications to protect the central nervous system under pathological conditions</article-title><source>J Biol Chem</source><year>2013</year><volume>288</volume><issue>6</issue><fpage>3831</fpage><lpage>3843</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.405654</pub-id><pub-id pub-id-type="pmid">23264628</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Dhammu</surname><given-names>TS</given-names></name><name><surname>Matsuda</surname><given-names>F</given-names></name><name><surname>Baarine</surname><given-names>M</given-names></name><name><surname>Dhindsa</surname><given-names>TS</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name></person-group><article-title>Promoting endothelial function by S-nitrosoglutathione through the HIF-1alpha/VEGF pathway stimulates neurorepair and functional recovery following experimental stroke in rats</article-title><source>Drug Des Dev Ther</source><year>2015</year><volume>9</volume><fpage>2233</fpage><lpage>2247</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S77115</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteman</surname><given-names>M</given-names></name><name><surname>Armstrong</surname><given-names>JS</given-names></name><name><surname>Cheung</surname><given-names>NS</given-names></name><name><surname>Siau</surname><given-names>JL</given-names></name><name><surname>Rose</surname><given-names>P</given-names></name><name><surname>Schantz</surname><given-names>JT</given-names></name><name><surname>Jones</surname><given-names>DP</given-names></name><name><surname>Halliwell</surname><given-names>B</given-names></name></person-group><article-title>Peroxynitrite mediates calcium-dependent mitochondrial dysfunction and cell death via activation of calpains</article-title><source>FASEB J</source><year>2004</year><volume>18</volume><issue>12</issue><fpage>1395</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1096/fj.03-1096fje</pub-id><pub-id pub-id-type="pmid">15240564</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Hall</surname><given-names>ED</given-names></name></person-group><article-title>Pharmacological evidence for a role of peroxynitrite in the pathophysiology of spinal cord injury</article-title><source>Exp Neurol</source><year>2009</year><volume>216</volume><issue>1</issue><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2008.11.025</pub-id><pub-id pub-id-type="pmid">19111721</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Rabchevsky</surname><given-names>AG</given-names></name><name><surname>Hall</surname><given-names>ED</given-names></name></person-group><article-title>Role of peroxynitrite in secondary oxidative damage after spinal cord injury</article-title><source>J Neurochem</source><year>2007</year><volume>100</volume><issue>3</issue><fpage>639</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.04312.x</pub-id><pub-id pub-id-type="pmid">17181549</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Im</surname><given-names>YB</given-names></name><name><surname>Shunmugavel</surname><given-names>A</given-names></name><name><surname>Gilg</surname><given-names>AG</given-names></name><name><surname>Dhindsa</surname><given-names>RK</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name></person-group><article-title>Administration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact</article-title><source>J Neuroinflammation</source><year>2009</year><volume>6</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-6-32</pub-id><pub-id pub-id-type="pmid">19889224</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilgen</surname><given-names>M</given-names></name></person-group><article-title>A new device for experimental modeling of central nervous system injuries</article-title><source>Neurorehabilit Neural Repair</source><year>2005</year><volume>19</volume><issue>3</issue><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1177/1545968305278635</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shunmugavel</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Chou</surname><given-names>PC</given-names></name><name><surname>Dhindsa</surname><given-names>RK</given-names></name><name><surname>Marcus</surname><given-names>M</given-names></name><name><surname>Copay</surname><given-names>AG</given-names></name><name><surname>Subach</surname><given-names>BR</given-names></name><name><surname>Schuler</surname><given-names>TC</given-names></name><name><surname>Bilgen</surname><given-names>M</given-names></name><name><surname>Orak</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Simvastatin protects bladder and renal functions following spinal cord injury in rats</article-title><source>J Inflamm</source><year>2010</year><volume>7</volume><issue>1</issue><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/1476-9255-7-17</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shunmugavel</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Hughes</surname><given-names>FM</given-names><suffix>Jr</suffix></name><name><surname>Purves</surname><given-names>JT</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name></person-group><article-title>S-nitrosoglutathione protects the spinal bladder: novel therapeutic approach to post-spinal cord injury bladder remodeling</article-title><source>Neurourol Urodyn</source><year>2015</year><volume>34</volume><issue>6</issue><fpage>519</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1002/nau.22619</pub-id><pub-id pub-id-type="pmid">24853799</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basso</surname><given-names>DM</given-names></name><name><surname>Beattie</surname><given-names>MS</given-names></name><name><surname>Bresnahan</surname><given-names>JC</given-names></name></person-group><article-title>A sensitive and reliable locomotor rating scale for open field testing in rats</article-title><source>J Neurotrauma</source><year>1995</year><volume>12</volume><issue>1</issue><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1089/neu.1995.12.1</pub-id><pub-id pub-id-type="pmid">7783230</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shunmugavel</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>MM</given-names></name><name><surname>Copay</surname><given-names>AG</given-names></name><name><surname>Subach</surname><given-names>BR</given-names></name><name><surname>Schuler</surname><given-names>TC</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name></person-group><article-title>S-nitrosoglutathione administration ameliorates cauda equina compression injury in rats</article-title><source>Neurosci Med</source><year>2012</year><volume>3</volume><issue>3</issue><fpage>294</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.4236/nm.2012.33034</pub-id><pub-id pub-id-type="pmid">23997981</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shunmugavel</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>MM</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Copay</surname><given-names>AG</given-names></name><name><surname>Subach</surname><given-names>BR</given-names></name><name><surname>Schuler</surname><given-names>TC</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name></person-group><article-title>Simvastatin ameliorates cauda equina compression injury in a rat model of lumbar spinal stenosis</article-title><source>J Neuroimmune Pharmacol</source><year>2013</year><volume>8</volume><issue>1</issue><fpage>274</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1007/s11481-012-9419-3</pub-id><pub-id pub-id-type="pmid">23188522</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Dhammu</surname><given-names>TS</given-names></name><name><surname>Matsuda</surname><given-names>F</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name></person-group><article-title>Blocking a vicious cycle nNOS/peroxynitrite/AMPK by S-nitrosoglutathione: implication for stroke therapy</article-title><source>BMC Neurosci</source><year>2015</year><volume>16</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/s12868-015-0179-x</pub-id><pub-id pub-id-type="pmid">26174015</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datto</surname><given-names>JP</given-names></name><name><surname>Bastidas</surname><given-names>JC</given-names></name><name><surname>Miller</surname><given-names>NL</given-names></name><name><surname>Shah</surname><given-names>AK</given-names></name><name><surname>Arheart</surname><given-names>KL</given-names></name><name><surname>Marcillo</surname><given-names>AE</given-names></name><name><surname>Dietrich</surname><given-names>WD</given-names></name><name><surname>Pearse</surname><given-names>DD</given-names></name></person-group><article-title>Female rats demonstrate improved locomotor recovery and greater preservation of white and gray matter after traumatic spinal cord injury compared to males</article-title><source>J Neurotrauma</source><year>2015</year><volume>32</volume><issue>15</issue><fpage>1146</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1089/neu.2014.3702</pub-id><pub-id pub-id-type="pmid">25715192</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>JK</given-names></name><name><surname>Miao</surname><given-names>L</given-names></name><name><surname>Calvert</surname><given-names>JW</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Louis Harkey</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>JH</given-names></name></person-group><article-title>A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat</article-title><source>Brain Res</source><year>2003</year><volume>959</volume><issue>1</issue><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(02)03717-4</pub-id><pub-id pub-id-type="pmid">12480155</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>MD</given-names></name><name><surname>Hulsebosch</surname><given-names>CE</given-names></name></person-group><article-title>Chronic central pain after spinal cord injury</article-title><source>J Neurotrauma</source><year>1997</year><volume>14</volume><issue>8</issue><fpage>517</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1089/neu.1997.14.517</pub-id><pub-id pub-id-type="pmid">9300563</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnerup</surname><given-names>NB</given-names></name></person-group><article-title>Pain in patients with spinal cord injury</article-title><source>Pain</source><year>2013</year><volume>154</volume><issue>Suppl 1</issue><fpage>S71</fpage><lpage>S76</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2012.12.007</pub-id><pub-id pub-id-type="pmid">23375163</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrico</surname><given-names>KM</given-names></name><name><surname>Vaishnav</surname><given-names>R</given-names></name><name><surname>Hall</surname><given-names>ED</given-names></name></person-group><article-title>Temporal and spatial dynamics of peroxynitrite-induced oxidative damage after spinal cord contusion injury</article-title><source>J Neurotrauma</source><year>2009</year><volume>26</volume><issue>8</issue><fpage>1369</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1089/neu.2008.0870</pub-id><pub-id pub-id-type="pmid">19419247</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>KK</given-names></name></person-group><article-title>Calpain and caspase: can you tell the difference?</article-title><source>Trends Neurosci</source><year>2000</year><volume>23</volume><issue>1</issue><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/S0166-2236(99)01479-4</pub-id><pub-id pub-id-type="pmid">10631785</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Son</surname><given-names>TG</given-names></name><name><surname>Mughal</surname><given-names>MR</given-names></name><name><surname>Greig</surname><given-names>NH</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name></person-group><article-title>Pregabalin suppresses calcium-mediated proteolysis and improves stroke outcome</article-title><source>Neurobiol Dis</source><year>2011</year><volume>41</volume><issue>3</issue><fpage>624</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2010.11.011</pub-id><pub-id pub-id-type="pmid">21111818</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carragher</surname><given-names>NO</given-names></name></person-group><article-title>Calpain inhibition: a therapeutic strategy targeting multiple disease states</article-title><source>Curr Pharm Des</source><year>2006</year><volume>12</volume><issue>5</issue><fpage>615</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.2174/138161206775474314</pub-id><pub-id pub-id-type="pmid">16472152</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacher</surname><given-names>P</given-names></name><name><surname>Beckman</surname><given-names>JS</given-names></name><name><surname>Liaudet</surname><given-names>L</given-names></name></person-group><article-title>Nitric oxide and peroxynitrite in health and disease</article-title><source>Physiol Rev</source><year>2007</year><volume>87</volume><issue>1</issue><fpage>315</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1152/physrev.00029.2006</pub-id><pub-id pub-id-type="pmid">17237348</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genovese</surname><given-names>T</given-names></name><name><surname>Mazzon</surname><given-names>E</given-names></name><name><surname>Esposito</surname><given-names>E</given-names></name><name><surname>Muia</surname><given-names>C</given-names></name><name><surname>Di Paola</surname><given-names>R</given-names></name><name><surname>Bramanti</surname><given-names>P</given-names></name><name><surname>Cuzzocrea</surname><given-names>S</given-names></name></person-group><article-title>Beneficial effects of FeTSPP, a peroxynitrite decomposition catalyst, in a mouse model of spinal cord injury</article-title><source>Free Radic Biol Med</source><year>2007</year><volume>43</volume><issue>5</issue><fpage>763</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2007.05.012</pub-id><pub-id pub-id-type="pmid">17664140</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>HS</given-names></name><name><surname>Badgaiyan</surname><given-names>RD</given-names></name><name><surname>Alm</surname><given-names>P</given-names></name><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Wiklund</surname><given-names>L</given-names></name></person-group><article-title>Neuroprotective effects of nitric oxide synthase inhibitors in spinal cord injury-induced pathophysiology and motor functions: an experimental study in the rat</article-title><source>Ann NY Acad Sci</source><year>2005</year><volume>1053</volume><fpage>422</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1196/annals.1344.037</pub-id><pub-id pub-id-type="pmid">16179549</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farooque</surname><given-names>M</given-names></name><name><surname>Isaksson</surname><given-names>J</given-names></name><name><surname>Olsson</surname><given-names>Y</given-names></name></person-group><article-title>Improved recovery after spinal cord injury in neuronal nitric oxide synthase-deficient mice but not in TNF-alpha-deficient mice</article-title><source>J Neurotrauma</source><year>2001</year><volume>18</volume><issue>1</issue><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1089/089771501750055811</pub-id><pub-id pub-id-type="pmid">11200245</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlawat</surname><given-names>A</given-names></name><name><surname>Rana</surname><given-names>A</given-names></name><name><surname>Goyal</surname><given-names>N</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name></person-group><article-title>Potential role of nitric oxide synthase isoforms in pathophysiology of neuropathic pain</article-title><source>Inflammopharmacology</source><year>2014</year><volume>22</volume><issue>5</issue><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1007/s10787-014-0213-0</pub-id><pub-id pub-id-type="pmid">25095760</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>ZW</given-names></name><name><surname>Miao</surname><given-names>WY</given-names></name><name><surname>Hu</surname><given-names>SQ</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhuo</surname><given-names>XL</given-names></name><name><surname>Zong</surname><given-names>YY</given-names></name><name><surname>Wu</surname><given-names>YP</given-names></name><name><surname>Zhang</surname><given-names>GY</given-names></name></person-group><article-title><italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor-dependent denitrosylation of neuronal nitric oxide synthase increase the enzyme activity</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><issue>12</issue><fpage>e52788</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0052788</pub-id><pub-id pub-id-type="pmid">23285183</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turtle</surname><given-names>JD</given-names></name><name><surname>Strain</surname><given-names>MM</given-names></name><name><surname>Aceves</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>YJ</given-names></name><name><surname>Reynolds</surname><given-names>JA</given-names></name><name><surname>Hook</surname><given-names>MA</given-names></name><name><surname>Grau</surname><given-names>JW</given-names></name></person-group><article-title>Pain input impairs recovery after spinal cord injury: treatment with lidocaine</article-title><source>J Neurotrauma</source><year>2017</year><volume>34</volume><issue>6</issue><fpage>1200</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1089/neu.2016.4778</pub-id><pub-id pub-id-type="pmid">27912032</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagen</surname><given-names>EM</given-names></name><name><surname>Rekand</surname><given-names>T</given-names></name></person-group><article-title>Management of neuropathic pain associated with spinal cord injury</article-title><source>Pain Ther</source><year>2015</year><volume>4</volume><issue>1</issue><fpage>51</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1007/s40122-015-0033-y</pub-id><pub-id pub-id-type="pmid">25744501</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanabe</surname><given-names>M</given-names></name><name><surname>Nagatani</surname><given-names>Y</given-names></name><name><surname>Saitoh</surname><given-names>K</given-names></name><name><surname>Takasu</surname><given-names>K</given-names></name><name><surname>Ono</surname><given-names>H</given-names></name></person-group><article-title>Pharmacological assessments of nitric oxide synthase isoforms and downstream diversity of NO signaling in the maintenance of thermal and mechanical hypersensitivity after peripheral nerve injury in mice</article-title><source>Neuropharmacology</source><year>2009</year><volume>56</volume><issue>3</issue><fpage>702</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.12.003</pub-id><pub-id pub-id-type="pmid">19111753</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leem</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Hulsebosch</surname><given-names>CE</given-names></name><name><surname>Gwak</surname><given-names>YS</given-names></name></person-group><article-title>Ionotropic glutamate receptors contribute to maintained neuronal hyperexcitability following spinal cord injury in rats</article-title><source>Exp Neurol</source><year>2010</year><volume>224</volume><issue>1</issue><fpage>321</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2010.02.012</pub-id><pub-id pub-id-type="pmid">20211179</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milligan</surname><given-names>ED</given-names></name><name><surname>Soderquist</surname><given-names>RG</given-names></name><name><surname>Malone</surname><given-names>SM</given-names></name><name><surname>Mahoney</surname><given-names>JH</given-names></name><name><surname>Hughes</surname><given-names>TS</given-names></name><name><surname>Langer</surname><given-names>SJ</given-names></name><name><surname>Sloane</surname><given-names>EM</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Leinwand</surname><given-names>LA</given-names></name><name><surname>Watkins</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain</article-title><source>Neuron Glia Biol</source><year>2006</year><volume>2</volume><issue>4</issue><fpage>293</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1017/S1740925X07000488</pub-id><pub-id pub-id-type="pmid">18079973</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milligan</surname><given-names>ED</given-names></name><name><surname>Sloane</surname><given-names>EM</given-names></name><name><surname>Langer</surname><given-names>SJ</given-names></name><name><surname>Hughes</surname><given-names>TS</given-names></name><name><surname>Jekich</surname><given-names>BM</given-names></name><name><surname>Frank</surname><given-names>MG</given-names></name><name><surname>Mahoney</surname><given-names>JH</given-names></name><name><surname>Levkoff</surname><given-names>LH</given-names></name><name><surname>Maier</surname><given-names>SF</given-names></name><name><surname>Cruz</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain</article-title><source>Pain</source><year>2006</year><volume>126</volume><issue>1&#8211;3</issue><fpage>294</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2006.07.009</pub-id><pub-id pub-id-type="pmid">16949747</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milligan</surname><given-names>ED</given-names></name><name><surname>Penzkover</surname><given-names>KR</given-names></name><name><surname>Soderquist</surname><given-names>RG</given-names></name><name><surname>Mahoney</surname><given-names>MJ</given-names></name></person-group><article-title>Spinal interleukin-10 therapy to treat peripheral neuropathic pain</article-title><source>Neuromodulation</source><year>2012</year><volume>15</volume><issue>6</issue><fpage>520</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1111/j.1525-1403.2012.00462.x</pub-id><pub-id pub-id-type="pmid">22672183</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuvel</surname><given-names>DJ</given-names></name><name><surname>Shunmugavel</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Singh</surname><given-names>I</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name></person-group><article-title>S-Nitrosoglutathione ameliorates acute renal dysfunction in a rat model of lipopolysaccharide-induced sepsis</article-title><source>J Pharm Pharmacol</source><year>2016</year><volume>68</volume><issue>10</issue><fpage>1310</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1111/jphp.12608</pub-id><pub-id pub-id-type="pmid">27484743</pub-id></element-citation></ref></ref-list></back></article>